Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR3 - TACC3||stomach cancer||predicted - sensitive||Futibatinib||Case Reports/Case Series||Actionable||In a Phase I trial, Lytgobi (futibatinib) treatment led to an overall objective response rate of 22% (2/9, 2 partial responses) and a disease control rate of 55.6% (5/9) in patients with gastric cancer harboring an FGFR2 amplification or FGFR3 rearrangement, including a partial response with a progression-free survival of 6.7 months and a duration of response of 5.4 months in a gastric cancer patient harboring FGFR3-TACC3 (PMID: 34551969; NCT02052778).||34551969|